Literature DB >> 23698536

Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents.

Rodrigo E Mendes1, Lalitagauri M Deshpande, Jihye Kim, Debra S Myers, James E Ross, Ronald N Jones.   

Abstract

This study describes a clinical case of a 71-year-old male with a history of ischemic cardiomyopathy after left ventricular assist device (LVAD) endocarditis caused by methicillin-resistant Staphylococcus epidermidis (MRSE) and a rare linezolid-resistant Streptococcus sanguinis strain (MIC, 32 μg/ml). The patient received courses of several antimicrobial agents, including linezolid for 79 days. The S. sanguinis strain had mutations in the 23S rRNA (T2211C, T2406C, G2576T, C2610T) and an amino acid substitution (N56D) in L22 and exhibited cross-resistance to ribosome-targeting agents.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23698536      PMCID： PMC3719607          DOI： 10.1128/JCM.00757-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.

Authors:  David J Farrell; Ian Morrissey; Sarah Bakker; Sylvie Buckridge; David Felmingham
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 2.  Antimicrobial resistance to linezolid.

Authors:  Venkata G Meka; Howard S Gold
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

Review 3.  Antibiotics that target protein synthesis.

Authors:  Lisa S McCoy; Yun Xie; Yitzhak Tor
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-11-22       Impact factor: 9.957

Review 4.  The ribosomal peptidyl transferase center: structure, function, evolution, inhibition.

Authors:  Norbert Polacek; Alexander S Mankin
Journal:  Crit Rev Biochem Mol Biol       Date:  2005 Sep-Oct       Impact factor: 8.250

5.  Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus.

Authors:  Nicole Wolter; Anthony M Smith; David J Farrell; William Schaffner; Matthew Moore; Cynthia G Whitney; James H Jorgensen; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; David J Farrell; Teresa Spanu; Giovanni Fadda; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2010-09-14       Impact factor: 5.790

7.  Linezolid surveillance results for the United States: LEADER surveillance program 2011.

Authors:  Robert K Flamm; Rodrigo E Mendes; James E Ross; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

8.  Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.

Authors:  Alan H Mutnick; Victoria Enne; Ronald N Jones
Journal:  Ann Pharmacother       Date:  2003-06       Impact factor: 3.154

9.  Single 23S rRNA mutations at the ribosomal peptidyl transferase centre confer resistance to valnemulin and other antibiotics in Mycobacterium smegmatis by perturbation of the drug binding pocket.

Authors:  Katherine S Long; Jacob Poehlsgaard; Lykke H Hansen; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Mol Microbiol       Date:  2009-01-16       Impact factor: 3.501

10.  Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center.

Authors:  Keith Miller; Colin J Dunsmore; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191
View more
  5 in total

1.  Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013.

Authors:  Rodrigo E Mendes; Patricia A Hogan; Jennifer M Streit; Ronald N Jones; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

3.  Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Jennifer M Streit; Patricia A Hogan; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.

Authors:  Rodrigo E Mendes; Robert K Flamm; Patricia A Hogan; James E Ross; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

Review 5.  Endocarditis in left ventricular assist device.

Authors:  Braghadheeswar Thyagarajan; Monisha Priyadarshini Kumar; Rutuja R Sikachi; Abhinav Agrawal
Journal:  Intractable Rare Dis Res       Date:  2016-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.